Merck explores new risks for biopharma with the EIU
![](/46/pdcnewsitem/04/11/11/Merck%20new.jpg)
New approaches for mitigating risk associated with new growth strategies.
Merck has announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape. The survey, sponsored by Merck, was conducted by the Economist Intelligence Unit (EIU), a leading resource for economic and business research, forecasting and analysis. Findings will be presented on 8 June at the 2016 BIO International Convention in San Francisco, California.
"In response to the uncertainty and disruption facing the biopharmaceutical industry, Merck has moved beyond old risk-management models and has adopted and is applying new strategies at the earliest stages of development and seeing them through to commercialization," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.
Study highlights include
48% of respondents are developing or will develop novel therapies, such as gene and cell therapies
Biopharmas anticipate entering South Korea, Indonesia and Taiwan in the next 5 years
Regulatory uncertainty tops the list of risks that biopharma executives think might disrupt their company's strategy in the next 5 years (32%)
80% of respondents are highly optimistic about their company's ability to bring new drug products to market over the next 5 years
Manufacturers in the biopharma industry face unprecedented challenges as they enter unfamiliar geographies, aggressively replenish pipelines and expand into novel areas such as gene and cell therapies requiring more complex development and production. The EIU study, detailed in The Changing Biopharma Risk Equation, examines how new growth strategies are creating exposure to different types of risk and explores options for successfully navigating this unexplored territory.
Survey respondents offered a global view with 31% from Europe, 30% from North America, 29% from Asia and 10% from the rest of the world. Responses also reflect the differences in view depending on company size, with 50% of participants coming from biopharmas with less than $500 million in revenues and 50% from larger players.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance